These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28195995)

  • 1. Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.
    Kingsberg SA; Kroll R; Goldstein I; Kushner H; Bernick B; Graham S; Mirkin S; Constantine GD
    Menopause; 2017 Aug; 24(8):894-899. PubMed ID: 28195995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
    Simon JA; Archer DF; Constantine GD; Pickar JH; Amadio JM; Bernick B; Graham S; Mirkin S
    Maturitas; 2017 May; 99():51-58. PubMed ID: 28364869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
    Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
    [No Abstract]   [Full Text] [Related]  

  • 4. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
    Constantine GD; Bouchard C; Pickar JH; Archer DF; Graham S; Bernick B; Mirkin S
    J Womens Health (Larchmt); 2017 Jun; 26(6):616-623. PubMed ID: 28355090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
    Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
    Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
    Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
    J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
    Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol.
    Archer DF; Constantine GD; Simon JA; Kushner H; Mayer P; Bernick B; Graham S; Mirkin S;
    Menopause; 2017 May; 24(5):510-516. PubMed ID: 28002201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical characteristics and properties of estradiol softgel vaginal inserts.
    Simon JA; Pickar JH; Shadiack AM; Warrier B; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Feb; 27(2):150-155. PubMed ID: 31663981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
    Liu JH; Bernick B; Mirkin S
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
    Constantine G; Millheiser LS; Kaunitz AM; Parish SJ; Graham S; Bernick B; Mirkin S
    Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
    Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
    Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule.
    Pickar JH; Amadio JM; Bernick BA; Mirkin S
    Climacteric; 2016 Apr; 19(2):181-7. PubMed ID: 26857443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
    Kingsberg SA; Wysocki S; Magnus L; Krychman ML
    J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G; Graham S; Koltun WD; Kingsberg SA
    J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.